BYSI BeyondSpring

BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting

BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting

NEW YORK, May 18, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that the Company and Memorial Sloan Kettering Cancer Center (MSK) will present a poster at the , taking place on June 2 through 6 in Chicago, IL.

The poster, titled, “​​Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant,” will be presented by Dr. Gunjan Shah, MD, MS, Assistant Attending Physician at MSKCC and Principal Investigator of the evaluating Plinabulin in combination with pegfilgrastim in multiple myeloma patients who undergo an autologous hematopoietic cell transplant (AHCT).

Additional presentation details are as follows:

  • Poster Session Date / Time: Monday, June 5, 2023, at 9 a.m. to 12 p.m. ET
  • Location: McCormick Place Convention Center, Hall A
  • Track: Hematologic Malignancies
  • Abstract / Poster Board No.: 8023 / 15

About BeyondSpring

(NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company is advancing its first-in-class lead asset, Plinabulin, as a direct anti-cancer agent in various cancer indications and to prevent chemotherapy-induced neutropenia. Its also includes three preclinical immuno-oncology assets. Additionally, BeyondSpring’s subsidiary, SEED Therapeutics, leverages a proprietary targeted protein degradation (TPD) drug discovery platform and has an initial R&D collaboration with Eli Lilly. Learn more by visiting , and follow us on and .

Investor Contact:

Media Contact:



EN
18/05/2023

Underlying

BYSIBeyondSpring

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BeyondSpring

 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxe...

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC. FLORHAM PARK, N.J., Dec. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immun...

December 12, 2025 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing ...

BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent survival benefit in anti-PD-(L)1-progressed NSCLC patients. Supported by anti-cancer efficacy and safety in signi...

December 11, 2025 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides...

BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update Two SITC 2025 presentations: First-in-class dendritic cell (DC) maturation agent Plinabulin drives immune re-sensitization in metastatic NSCLC patients who had progressed after PD-1/L1 inhibitors with disease control rate of 85% in combination with docetaxel and Keytruda. Mechanism studies with MD Anderson collaborators showed DC maturation and M1 macrophage polarization via a Plinabulin specific GEF-H1 dependent mechanism in responding patients with Plinabulin, PD-1 inhibitor and radiation. SEED, co-fou...

November 12, 2025 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provide...

BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment ASCO 2025 presentation: First-in-class agent Plinabulin drives immune re-sensitization in NSCLC patients progressed to PD-1/L1 therapiesMed (Cell Press) Publication with MD Anderson Collaboration highlights Plinabulin’s rapid dendritic cell activation in responding patients across eight cancer types who failed prior immunotherapySEED Therapeutics’ RBM39 degrader ST-01156 clears FDA IND and advances toward Phase 1...

August 13, 2025 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showin...

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated an overall response rate (ORR) of 23% and a disease control rate (DCR) of 54% in non-irradiated lesions.Biomarker analysis linked Plinabulin’s mechanism to GEF-H1–dependent dendritic cell maturation, offering the potential to pre-select patients at baseline and predict clinical respo...

July 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch